Table 2 Associations between metformin use at hospital admission for AMI and MACE over median follow-up of 343 (IQR: 1–1436) days
| Â | Number of patients experiencing event (%) | Unadjusted | Adjusteda | |||
|---|---|---|---|---|---|---|
Metformin (N = 2576) | Other (N = 1454) | Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | |
Primary endpoint | ||||||
 MACE (composite of cardiovascular mortality, AMI and stroke) | 1551 (60.2) | 899 (61.8) | 0.95 (0.88–1.03) | 0.239 | 1.09 (1.01–1.19) | 0.034 |
Components of primary endpoint | ||||||
 Cardiovascular mortality | 894 (34.7%) | 584 (40.2%) | 0.84 (0.76–0.93) | 0.001 | 1.06 (0.96–1.17) | 0.275 |
 AMI | 807 (31.3%) | 433 (29.8%) | 1.01 (0.90–1.14) | 0.887 | 1.06 (0.94–1.20) | 0.363 |
 Stroke | 294 (11.4%) | 195 (13.4%) | 0.84 (0.70–1.00) | 0.051 | 0.99 (0.82–1.19) | 0.904 |
Secondary endpoints | ||||||
 All-cause mortality | 1423 (55.2%) | 1020 (70.2%) | 0.77 (0.71–0.83) | < 0.001 | 0.97 (0.89–1.04) | 0.395 |
 HF hospitalisation | 589 (22.9) | 313 (21.5) | 1.01 (0.88–1.16) | 0.918 | 1.13 (0.98–1.30) | 0.092 |